ArticleImmunology2001
Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies.
Article in Immunology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 98 citations in OpenAlex.
- CD97/ADGRE5 attenuates the induction of adaptive type 2 immune responses in allergic asthma.Nature communications · 2026Article
- Critical Role of CD55 in Controlling Wound Healing.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Emerging role of complement in COVID-19 and other respiratory virus diseases.Cellular and molecular life sciences : CMLS · 2024Review
- Insights Into the Emergence of Paroxysmal Nocturnal Hemoglobinuria.Frontiers in immunology · 2021Review
- MicroRNA-338-5p plays a tumor suppressor role in glioma through inhibition of the MAPK-signaling pathway by binding to FOXD1.Journal of cancer research and clinical oncology · 2018Article
- Late stage definitive endodermal differentiation can be defined by Daf1 expression.BMC developmental biology · 2016Article
- Complement activation at the motor end-plates in amyotrophic lateral sclerosis.Journal of neuroinflammation · 2016Article
- Deficiency of CC chemokine ligand 2 and decay-accelerating factor causes retinal degeneration in mice.Experimental eye research · 2015Article
- A tandem repeat in decay accelerating factor 1 is associated with severity of murine mercury-induced autoimmunity.Autoimmune diseases · 2014Article
- The role of decay accelerating factor in environmentally induced and idiopathic systemic autoimmune disease.Autoimmune diseases · 2014Review
- Complement regulation in renal disease models.Seminars in nephrology · 2013Review
- Mice lacking C1q are protected from high fat diet-induced hepatic insulin resistance and impaired glucose homeostasis.The Journal of biological chemistry · 2013Article
- Mice overexpressing CD97 in intestinal epithelial cells provide a unique model for mammalian postnatal intestinal cylindrical growth.Molecular biology of the cell · 2013Article
- Cell surface complement regulators moderate experimental myasthenia gravis pathology.Muscle & nerve · 2013Article
- A molecular signature for purified definitive endoderm guides differentiation and isolation of endoderm from mouse and human embryonic stem cells.Stem cells and development · 2012Article
- Depletion of complement does not impact initiation of xenobiotic-induced autoimmune disease.Immunology · 2012Article
- Immunoprotective properties of primary Sertoli cells in mice: potential functional pathways that confer immune privilege.Biology of reproduction · 2012Article
- Virus-host coevolution in a persistently coxsackievirus B3-infected cardiomyocyte cell line.Journal of virology · 2011Article
- Complement regulates CD4 T-cell help to CD8 T cells required for murine allograft rejection.The American journal of pathology · 2011Article
- Redox signaling and the innate immune system in alcoholic liver disease.Antioxidants & redox signaling · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
Decay-accelerating factor (DAF) is a membrane regulator of C3 activation that protects self cells from autologous complement attack. In humans, DAF is uniformly expressed as a glycosylphosphatidylinositol (GPI)-anchored molecule. In mice, both GPI-anchored and transmembrane-anchored DAF proteins are produced, each of which can be derived from two different genes (Daf1 and Daf2). In this report, we describe a Daf1 gene knock-out mouse arising as the first product of a strategy for targeting one or both Daf genes. As part of the work, we characterize recently described monoclonal antibodies against murine DAF protein using deletion mutants synthesized in yeast, and then employ the monoclonal antibodies in conjunction with wild-type and the Daf1 knock-out mice to determine the tissue distribution of the mouse Daf1 and Daf2 gene products. To enhance the immunohistochemical detection of murine DAF protein, we utilized the sensitive tyramide fluorescence method. In wild-type mice, we found strong DAF labelling of glomeruli, airway and gut epithelium, the spleen, vascular endothelium throughout all tissues, and seminiferous tubules of the testis. In Daf1 knock-out mice, DAF labelling was ablated in most tissues, but strong labelling of the testis and splenic dendritic cells remained. In both sites, reverse transcription-polymerase chain reaction analyses identified both GPI and transmembrane forms of Daf2 gene-derived protein. The results have relevance for studies of in vivo murine DAF function and of murine DAF structure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.